About the Company
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GBT News
Global Blood Therapeutics
Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for around $5 billion, according to press reports.
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it initiated the Phase 2 portion of a planned Phase 2/3 ...
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
Previously, he was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. where he led the company from a pre-clinical startup to a global commercial company with a focus on ...
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
Nikhil has worked in life sciences in roles of increasing responsibility throughout his career, including Global Blood Therapeutics, Inc. and ZS Pharma, Inc. He graduated with Honors from the Sri ...
Why Is Blood Cancer Focused Marker Therapeutics Stock Trading Higher Today?
Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary ... Dimon Pours Cold Water On US Economic Optimism, Flags Global Tensions, Financial Shifts MT-601 treatment was well tolerated ...
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Tr…
SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION ...
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq ... Ph.D., will participate in a fireside chat presentation at the Leerink Partners 2024 Global Biopharma Conference on ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call ... Our revenue performance reflects the continued outstanding work of our global customer-facing teams and our successful efforts ...
Global Blood Therapeutics
This page shows the latest Global Blood Therapeutics news and features for those working in and with pharma, biotech and healthcare. Pfizer has announced the completion of its acquisition of Global ...
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
He joins from CareDx, Inc., where he led a global accounting team and oversaw all aspects of financial reporting. Nikhil has worked in life sciences in roles of increasing responsibility throughout ...
Loading the latest forecasts...